Methylprednisolone (as Methylprednisolone sodium succinate)
125 mgSolu-Medrone 125 mg powder and solvent for solution for
injection vials| 1 vialP£ 4. 75
Methylprednisolone (as Methylprednisolone sodium succinate)
500 mgSolu-Medrone 500 mg powder and solvent for solution for
injection vials| 1 vialP£ 9. 60
Methylprednisolone (as Methylprednisolone sodium succinate)
1 gramSolu-Medrone 1 g powder and solvent for solution for injection
vials| 1 vialP£ 17. 30
Methylprednisolone (as Methylprednisolone sodium succinate)
2 gramSolu-Medrone 2 g powder and solvent for solution for injection
vials| 1 vialP£ 32. 86
Tablet
CAUTIONARY AND ADVISORY LABELS10, 21
▶Medrone(Pfizer Ltd)
Methylprednisolone 2 mgMedrone 2 mg tablets| 30 tabletP
£ 3. 88
Methylprednisolone 4 mgMedrone 4 mg tablets| 30 tabletP
£ 6. 19
Methylprednisolone 16 mgMedrone 16 mg tablets| 30 tabletP
£ 17. 17
Methylprednisolone 100 mgMedrone 100 mg tablets|
20 tabletP£ 48. 32
Suspension for injection
CAUTIONARY AND ADVISORY LABELS 10
▶Depo-Medrone(Pfizer Ltd)
Methylprednisolone acetate 40 mg per 1 mlDepo-Medrone
40 mg/ 1 ml suspension for injection vials| 1 vialP£ 3. 44 DT =
£ 3. 44 | 10 vialP£ 34. 04
Depo-Medrone 80 mg/ 2 ml suspension for injection vials| 1 vialP
£ 6. 18 DT = £ 6. 18 | 10 vialP£ 61. 39
Depo-Medrone 120 mg/ 3 ml suspension for injection vials|
1 vialP£ 8. 96 DT = £ 8. 96 | 10 vialP£ 88. 81
eiiiiF 436Prednisolone 21-Dec-2017
lINDICATIONS AND DOSE
Severe croup (before transfer to hospital)|Mild croup that
might cause complications (before transfer to hospital)
▶BY MOUTH
▶Child: 1 – 2 mg/kg
Mild to moderate acute asthma (when oral corticosteroid
taken for more than a few days)|Severe or life-
threatening acute asthma (when oral corticosteroid
taken for more than a few days)
▶BY MOUTH
▶Child 1 month–11 years: 2 mg/kg once daily (max. per
dose 60 mg) for up to 3 days, longer if necessary
Mild to moderate acute asthma|Severe or life-threatening
acute asthma
▶BY MOUTH
▶Child 1 month–11 years: 1 – 2 mg/kg once daily (max. per
dose 40 mg) for up to 3 days, longer if necessary
▶Child 12–17 years: 40 – 50 mg daily for at least 5 days
Autoimmune inflammatory disorders (including juvenile
idiopathic arthritis, connective tissue disorders and
systemic lupus erythematosus)
▶BY MOUTH
▶Child:Initially 1 – 2 mg/kg once daily, to be reduced
after a few days if appropriate; maximum 60 mg per day
Autoimmune hepatitis
▶BY MOUTH
▶Child:Initially 2 mg/kg once daily, to then be reduced
to minimum effective dose; maximum 40 mg per day
Corticosteroid replacement therapy
▶BY MOUTH
▶Child 12–17 years: 2 – 2. 5 mg/m^2 daily in 1 – 2 divided
doses, adjusted according to response
Infantile spasms
▶BY MOUTH
▶Child 1 month–1 year:Initially 10 mg 4 times a day for
14 days; increased to 20 mg 3 times a day for 7 days ifseizures not controlled after initial 7 days, reduce dose
gradually over 15 days until stopped
Infantile spasms (dose reduction in patient taking 40 mg
daily)
▶BY MOUTH
▶Child 1 month–1 year:Reduced in steps of 10 mg every
5 days, then stop
Infantile spasms (dose reduction in patient taking 60 mg
daily)
▶BY MOUTH
▶Child 1 month–1 year:Reduced to 40 mg daily for 5 days,
then reduced to 20 mg daily for 5 days, then reduced to
10 mg daily for 5 days and then stop
Idiopathic thrombocytopenic purpura
▶BY MOUTH
▶Child 1–9 years: 1 – 2 mg/kg daily for maximum of
14 days, alternatively 4 mg/kg daily for a maximum of
4 days
Nephrotic syndrome
▶BY MOUTH
▶Child:Initially 60 mg/m^2 once daily for 4 – 6 weeks until
proteinuria ceases, then reduced to 40 mg/m^2 once
daily on alternate days for 4 – 6 weeks, then withdraw
by reducing dose gradually; maximum 80 mg per day
Nephrotic syndrome (prevention of relapse)
▶BY MOUTH
▶Child: 0. 5 – 1 mg/kg once daily or on alternate days for
3 – 6 months
Ulcerative colitis|Crohn’s disease
▶BY MOUTH
▶Child 2–17 years: 2 mg/kg once daily (max. per dose
60 mg) until remission occurs, followed by reducing
doses
Pneumocystis pneumonia in moderate to severe
infections associated with HIV infection
▶BY MOUTH
▶Child: 2 mg/kg daily for 5 days, the dose is then reduced
over the next 16 days and then stopped, corticosteroid
treatment should ideally be started at the same time as
the anti-pneumocystis therapy and certainly no later
than 24 – 72 hours afterwards, the corticosteroid should
be withdrawn before anti-pneumocystis treatment is
complete; maximum 80 mg per day
Proctitis
▶BY RECTUM USING RECTAL FOAM
▶Child 12–17 years: 1 metered application 1 – 2 times a day
for 2 weeks, continued for further 2 weeks if good
response, to be inserted into the rectum, 1 metered
application contains 20 mg prednisolone
▶BY RECTUM USING SUPPOSITORIES
▶Child 2–17 years: 5 mg twice daily, to be inserted in to
the rectum morning and night, after a bowel
movement
Distal ulcerative colitis
▶BY RECTUM USING RECTAL FOAM
▶Child 12–17 years: 1 metered application 1 – 2 times a day
for 2 weeks, continued for further 2 weeks if good
response, to be inserted into the rectum, 1 metered
application contains 20 mg prednisolone
Rectal complications of Crohn’s disease
▶BY RECTUM USING SUPPOSITORIES
▶Child 2–17 years: 5 mg twice daily, to be inserted in to
the rectum morning and night, after a bowel
movement442 Corticosteroid responsive conditions BNFC 2018 – 2019
Endocrine system6